Betagenon has announced that James Hall has joined the company as Chief Executive Officer.
James Hall brings senior healthcare and life science experience, including 12 years with AstraZeneca. While there, he held several commercial, R&D, and Business Development roles, including VP Global Marketing for the CV/GI Therapy Area, Global Product VP for Crestor, and VP Evaluation for the CV/Metabolism/Renal Therapy Area. Before this, he was a member of the Pharmaceutical/Medical Products practice at McKinsey & Co.
He has a BM, BCh in Clinical Medicine, and a D. Phil in Cell Physiology from Oxford University where he was a Rhodes Scholar.
“I am incredibly excited to join Betagenon as we build on the scientific leadership of Thomas and the team, and drive to clinical proof of concept and show what direct activation of AMPK can deliver to patients,” says Hall.
Gunnar Olsson – New Chairman of the Board
Betagenon also announced that Dr. Gunnar Olsson, MD, Ph.D., has been elected as Chairman of the Board at the recent AGM. Dr. Olsson brings more than 30 years of experience in drug development, including 25 years at AstraZeneca. While at AstraZeneca Dr. Olsson held several senior roles in Global R&D including Senior VP and leader of the CV & GI Therapy Area. He is certified in Cardiology and Internal Medicine in hospitals associated with Karolinska Institutet, where he was an adjunct professor for 12 years. In recent years Dr. Olsson has worked with innovative biotech companies in the Scandinavian region as a board member or advisor. He is currently Chairman of the Board of IRLAB AB and Athera Biotechnologies AB and is a member of the Board of Gesynta AB.
Dr. Olsson succeeds Andreas Nordberg as Chairman. Mr. Nordberg will continue as a member of the Board.
Photo of James Hall: Betagenon